Home > Insider Trading > Filing (0000902664-17-004365)

Filing Details

Accession Number:: 0000902664-17-004365
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-15 17:48:56
Reporting Period:: 2017-11-14

Accepted Time:: 2017-11-15 17:48:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
722830	Immunomedics Inc	IMMU	In Vitro & In Vivo Diagnostic Substances (2835)	611009366

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1701815	Behzad Aghazadeh	C/O Venbio Select Advisor Llc 120 W. 45Th Street, 28Th Floor New York NY 10036		Yes	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value Per Share (The "Common Stock")	Acquisiton	2017-11-14	1,150,000	$10.39	15,889,461	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-11-15	175,000	$10.97	16,064,461	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.2 to $10.8403 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.6584 to $11.3049 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.